and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the development of Richter transformation after chimeric antigen receptor T-cell (CAR-T) therapy.
CAR-T therapy is a revolutionary therapy that trains the patient’s own cells to attack their CLL / SLL. The science can be somewhat complicated and advanced, but the results can be amazing. You
CAR-T Ed Forum: CAR-T Cell Therapy in CLL / SLL Recorded Wednesday, April 21, 2021 https://www.youtube.com/watch?v=8hQut-tEhB4 Continue to Session 4: CLL Society’s Overview of Programs and Services CLL Society Resources Download Slides CAR-T
CAR-T Ed ForumImmunotherapy: A New Paradigm for Treatment Recorded Wednesday, April 21, 2021 https://youtu.be/oNG2Wxw4iqY Continue to Session 3: CAR-T Cell Therapy in CLL / SLL CLL Society Resources Download Slides CAR-T Webpage CLL
To learn more information about how this revolutionary “living drug” works, the steps involved, insurance coverage, and eligibility, please read this short CAR-T infographic as well as other topics from the CAR-T Working Group.
The FDA’s mandatory plans to manage drug risks or REMS (Risk Evaluation and Mitigation Strategies) were dropped for CAR-T, making it more accessible in CLL.
CAR-T is an option for CLL. Its expense and complexity make it inaccessible to many. Making CAR-T cells in the body (in vivo) changes everything.
By never freezing the locally produced CAR-T cells, disappointing response rates for relapsed/refractory CLL and Richter’s Syndrome patients are greatly improved
CAR-T is an effective but underused option in cancer. Successful engineering of CAR-T cells in vivo in nonhuman primates has now been achieved.
